Comment: A recommended pharma practice that is highly active in transaction-related advice. Mehdorn boasts social law expertise here, while Homberg has a solid reputation for his advice on licensing cooperations and biotech transactions. More or less unnoticed in the market, the pharma practice has found a niche that is a very current topic: the digitalization of work processes in the healthcare industry. With this comes a more direct entry to advising on e-health applications than many of its competitors have. The addition of a ?public procurement team last year strengthened the firm’s internal competence and can be exploited in the future to advise clients even more extensively.
Strengths: Transactions (biotech industry and hospital sector).
Recommended: Peter Homberg, Dr. Ilka Mehdorn.
Practice: Focus on drafting contracts (incl. selective contracts) as well as social litigation and arbitration proceedings. Also IP licensing, cooperation agreements and research and development contracts. Pharma advertising and authorization. Strong overlaps with ?antitrust and public procurement. Also M&A transactions (esp. in the hospital sector), as well as industry-related tax and employment law. Clients: pharma research companies, medical product manufacturers and biotech companies. Health insurance companies, clinics and medical associations. (5 partners, 1 counsel, 3 associates)
Clients: ?? Bayer against product counterfeiters; Roche Diagnostics in tenders concerning lab diagnostics and blood sugar measurement; GFS in review proceedings against health insurers on billing services; AbbVie on supply chains and inquiries from the EMA; Immunic in financing rounds; GP contract association in administrative procedure.
  • Teilen